...
首页> 外文期刊>Advances in therapy. >Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: Integrated analysis of two clinical studies
【24h】

Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: Integrated analysis of two clinical studies

机译:白内障手术后使用洛替泼诺依他宝酯眼用凝胶0.5%:两项临床研究的综合分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Introduction: We aimed to evaluate the safety and efficacy of loteprednol etabonate (LE) gel 0.5% compared with vehicle in the treatment of postoperative inflammation and pain following cataract surgery, using the integrated analysis of data from two identical, prospective, multicenter, randomized, double-masked, parallel-group, vehicle-controlled trials. Methods: Patients with anterior chamber cell (ACC) inflammation ≥ grade 2 (6-15 cells) 1 day post-surgery were randomized to receive 1 or 2 drops of LE gel 0.5% or vehicle 4 times per day instilled in the study eye for 14 days. Primary outcome measures included the proportion of patients with complete resolution of ACC and grade 0 (no) pain on postoperative Day 8. Safety endpoints included adverse events (AEs), changes from baseline in intraocular pressure (IOP) and visual acuity (VA), biomicroscopy, and funduscopy findings. Gel comfort was graded by patients according to drop sensation. Results: The intent-to-treat population included 813 patients (409 LE gel 0.5% and 404 vehicle). At postoperative Day 8, 30.8% and 15.1% of patients randomized to LE gel 0.5% or vehicle, respectively, had complete resolution of ACC, while 74.3% and 43.8% of patients, respectively, had grade 0 pain (P < 0.001 for both). Tolerability assessments for ocular itching, photophobia, and tearing favored LE gel 0.5% compared with vehicle at different time points beginning at Day 3. Two patients in the LE gel 0.5% group and 1 patient in the vehicle group exhibited a transient treatment-emergent increase in IOP ≥ 10 mmHg. Treatment-related AEs were generally mild to moderate and occurred less frequently with LE gel 0.5% than with vehicle. Reports of treatment-related blurred vision were rare (n = 2, vehicle). Conclusion: LE gel 0.5% was efficacious and well tolerated in the treatment of postoperative pain and inflammation following ocular surgery, with minimal risk of IOP elevation.
机译:简介:我们旨在通过对来自两个相同,前瞻性,多中心,随机,双掩蔽,平行组,车辆控制试验。方法:术后1天,前房细胞(ACC)炎症≥2级(6-15个细胞)的患者随机接受研究眼中每天滴注1或2滴0.5%的LE凝胶或溶媒4次, 14天主要结局指标包括术后第8天ACC完全缓解且0级疼痛(无)的患者比例。安全性终点指标包括不良事件(AE),眼压(IOP)和视力(VA)的基线变化,生物显微镜检查和眼底检查结果。患者根据跌落感觉对凝胶舒适度进行分级。结果:意向性治疗人群包括813例患者(409 LE凝胶0.5%和404载体)。术后第8天,分别随机分入0.5%LE凝胶或溶媒的30.8%和15.1%的患者ACC完全缓解,而分别为0级疼痛的患者分别为74.3%和43.8%(P均<0.001) )。从第3天开始,在不同时间点对眼瘙痒,畏光和流泪的耐受性评估均优于媒介物,LE凝胶为0.5%。LE凝胶0.5%组中的2例患者和媒介物组中的1例患者出现了短暂的治疗紧急情况在IOP≥10 mmHg中。与治疗有关的AE一般为轻度至中度,与0.5%的LE凝胶相比,LE凝胶发生的频率更低。与治疗相关的视力模糊的报道很少(n = 2,媒介物)。结论:LE凝胶0.5%在眼科手术后的术后疼痛和炎症的治疗中有效且耐受性良好,IOP升高的风险最小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号